Immunic Inc (NASDAQ:IMUX) — Market Cap & Net Worth
Market Cap & Net Worth: Immunic Inc (IMUX)
Immunic Inc (NASDAQ:IMUX) has a market capitalization of $163.08 Million ($163.08 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17295 globally and #3893 in its home market, demonstrating a 950.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunic Inc's stock price $9.65 by its total outstanding shares 130464825 (130.46 Million). Analyse Immunic Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
Immunic Inc Market Cap History: 2015 to 2026
Immunic Inc's market capitalization history from 2015 to 2026. Data shows change from $60.12 Billion to $1.26 Billion (-26.58% CAGR).
Index Memberships
Immunic Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #476 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1694 of 3165 |
Weight: Immunic Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunic Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunic Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3783479.93x
Immunic Inc's market cap is 3783479.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $22.70 Billion | $6.00K | -$40.97 Million | 3783479.93x | N/A |
Competitor Companies of IMUX by Market Capitalization
Companies near Immunic Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Immunic Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Immunic Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Immunic Inc's market cap moved from $60.12 Billion to $ 1.26 Billion, with a yearly change of -26.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.26 Billion | +1708.13% |
| 2025 | $69.63 Million | -46.63% |
| 2024 | $130.46 Million | -33.33% |
| 2023 | $195.70 Million | +7.14% |
| 2022 | $182.65 Million | -85.37% |
| 2021 | $1.25 Billion | -37.41% |
| 2020 | $1.99 Billion | +57.63% |
| 2019 | $1.27 Billion | +30.38% |
| 2018 | $970.66 Million | -96.87% |
| 2017 | $31.05 Billion | +36.78% |
| 2016 | $22.70 Billion | -62.24% |
| 2015 | $60.12 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Immunic Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $163.08 Million USD |
| MoneyControl | $163.08 Million USD |
| MarketWatch | $163.08 Million USD |
| marketcap.company | $163.08 Million USD |
| Reuters | $163.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more